Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Zimmermann, P; Sourij, H; Aberer, F; Rilstone, S; Schierbauer, J; Moser, O.
SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?
J Cardiovasc Dev Dis. 2023; 10(12): 478 Doi: 10.3390/jcdd10120478 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Leading authors Med Uni Graz
Moser Othmar
Co-authors Med Uni Graz
Aberer Felix
Sourij Harald
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
The coronavirus disease (COVID)-19 has turned into a pandemic causing a global public health crisis. While acute COVID-19 mainly affects the respiratory system and can cause acute respiratory distress syndrome, an association with persistent inflammatory stress affecting different organ systems has been elucidated in long COVID syndrome (LCS). Increased severity and mortality rates have been reported due to cardiophysiological and metabolic systemic disorders as well as multiorgan failure in COVID-19, additionally accompanied by chronic dyspnea and fatigue in LCS. Hence, novel therapies have been tested to improve the outcomes of LCS of which one potential candidate might be sodium-glucose cotransporter 2 (SGLT2) inhibitors. The aim of this narrative review was to discuss rationales for investigating SGLT2 inhibitor therapy in people suffering from LCS. In this regard, we discuss their potential positive effects-next to the well described "cardio-renal-metabolic" conditions-with a focus on potential anti-inflammatory and beneficial systemic effects in LCS. However, potential beneficial as well as potential disadvantageous effects of SGLT2 inhibitors on the prevalence and long-term outcomes of COVID-19 will need to be established in ongoing research.

Find related publications in this database (Keywords)
coronavirus disease (COVID)-19
long COVID syndrome
sodium-glucose cotransporter 2 inhibitors
SGLT2 inhibitors
cytokine storm
cardiovascular disorders
long COVID and cardiovascular sequelae
© Med Uni Graz • Imprint